GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline filed an Rx-to-OTC switch application for Xenical (orlistat 60 mg) in June, the firm announced July 28
You may also be interested in...
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug